All Oncology News

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

LV20.19 CAR T therapy produced an 88% CR rate and 100% ORR in relapsed/refractory mantle cell lymphoma.

Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

The FDA accepted an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations after prior endocrine therapy.

The FDA granted orphan drug designation to SAR446523 for relapsed/refractory multiple myeloma.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

Tanios S. Bekaii-Saab, MD, highlights how HER2-directed agents, chemoimmunotherapy, and biomarker-driven strategies are expanding options for biliary tract cancers.

Martin Dreyling, MD, PhD, discusses clinical trial findings with acalabrutinib plus BR in patients with high-risk mantle cell lymphoma.

The FDA granted accelerated approval to zongertinib for pretreated, unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.

Richard Bleicher, MD, FACS, discusses using a novel method to analyze tumor growth rates.

China’s NMPA has accepted the sNDA for first-line toripalimab plus disitamab vedotin in HER2-expressing locally advanced or metastatic urothelial carcinoma.

The FDA granted regenerative medicine advanced therapy designation to GLPG5101 for relapsed/refractory mantle cell lymphoma.

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

Lung cancer experts share upcoming, potentially practice-informing clinical trials that are expected to read out in the second half of 2025.

Alberto Farolfi, MD, PhD, shares results from a real-world study of first-line bevacizumab, pembrolizumab, and platinum chemotherapy in cervical cancer.

Kathleen A. Dorritie, MD, highlights important NCCN guideline updates and research to watch in hematologic malignancies.

Timothy Gershon, MD, PhD, discusses how the FDA approval of mirdametinib will affect the treatment paradigm for adult patients with NF1-associated PNs.

Epcoritamab plus rituximab and lenalidomide met the dual primary end points of the EPCORE FL-1 in relapsed/refractory follicular lymphoma.

ASCO updated their clinical practice guidelines for stage IV NSCLC with or without a driver alteration.

The MD Anderson Cancer Center was ranked number one in the nation for cancer care in U.S. News & World Report’s 2024-25 "Best Hospitals" survey.

The NCCN Clinical Practice Guidelines in Oncology for SCLC added new recommendations for LEMS, the use of amifampridine, and VGCC antibody testing.

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

Birelentinib received fast track designation from the FDA for relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Rachel E. Sanborn, MD, discusses the novel IB6-directed ADC sigvotatug vedotin for the treatment of patients with NSCLC.

Kathleen A. Dorritie, MD, discusses 2 clinical scenario cases to showcase differences in the management of newly diagnosed vs relapsed/refractory CLL.

The FDA granted accelerated approval to dordaviprone for patients at least 1 year of age with progressive H3K27M-mutated diffuse midline glioma.

Prerna Mewawalla, MD, highlights sequencing strategies with CAR T-cell therapy and bispecific antibodies in managing relapsed/refractory multiple myeloma.

Pamiparib with paclitaxel, carboplatin, and bevacizumab yields high complete cytoreduction rates, manageable safety in advanced ovarian cancer.

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.